| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 30 | 2022 | 167 | 5.610 |
Why?
|
| Receptors, Estrogen | 25 | 2019 | 35 | 4.290 |
Why?
|
| Lung Neoplasms | 12 | 2018 | 25 | 3.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 12 | 2018 | 13 | 2.950 |
Why?
|
| Signal Transduction | 18 | 2021 | 180 | 2.840 |
Why?
|
| Humans | 56 | 2022 | 2493 | 2.120 |
Why?
|
| Receptors, Progesterone | 6 | 2021 | 9 | 2.050 |
Why?
|
| Female | 54 | 2022 | 1733 | 2.010 |
Why?
|
| Estrogens | 14 | 2022 | 25 | 1.830 |
Why?
|
| Antineoplastic Agents | 9 | 2017 | 61 | 1.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 16 | 1.670 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2019 | 6 | 1.670 |
Why?
|
| Cell Membrane | 19 | 2017 | 31 | 1.600 |
Why?
|
| Estrogen Receptor beta | 4 | 2015 | 10 | 1.460 |
Why?
|
| Animals | 46 | 2019 | 1238 | 1.360 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2017 | 17 | 1.290 |
Why?
|
| Estradiol | 17 | 2013 | 50 | 1.190 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2017 | 7 | 1.180 |
Why?
|
| Receptor, ErbB-2 | 11 | 2019 | 28 | 1.150 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 138 | 1.000 |
Why?
|
| ErbB Receptors | 7 | 2016 | 13 | 0.980 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2019 | 30 | 0.950 |
Why?
|
| Mice | 19 | 2019 | 508 | 0.920 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2019 | 4 | 0.920 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2017 | 27 | 0.890 |
Why?
|
| Aromatase | 5 | 2011 | 6 | 0.880 |
Why?
|
| Estrogen Receptor Modulators | 5 | 2013 | 5 | 0.880 |
Why?
|
| Cell Proliferation | 7 | 2019 | 110 | 0.870 |
Why?
|
| Mammary Glands, Human | 1 | 2021 | 3 | 0.800 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2019 | 77 | 0.750 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 17 | 0.740 |
Why?
|
| Estrogen Antagonists | 2 | 2019 | 4 | 0.730 |
Why?
|
| Mice, Nude | 15 | 2019 | 36 | 0.720 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 4 | 0.720 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 10 | 0.690 |
Why?
|
| Pyrazoles | 2 | 2017 | 9 | 0.680 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 1 | 0.670 |
Why?
|
| Phenylthiohydantoin | 1 | 2017 | 2 | 0.640 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 6 | 0.640 |
Why?
|
| Triazines | 1 | 2017 | 6 | 0.640 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 7 | 0.640 |
Why?
|
| Pyrimidines | 1 | 2017 | 6 | 0.640 |
Why?
|
| Pyrroles | 1 | 2017 | 6 | 0.640 |
Why?
|
| Cell Nucleus | 6 | 2011 | 26 | 0.600 |
Why?
|
| Hormones | 4 | 2005 | 12 | 0.590 |
Why?
|
| Cisplatin | 4 | 2002 | 6 | 0.530 |
Why?
|
| Somatomedins | 1 | 2015 | 4 | 0.530 |
Why?
|
| Membrane Proteins | 3 | 2017 | 15 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 5 | 2004 | 19 | 0.470 |
Why?
|
| Aromatase Inhibitors | 4 | 2007 | 4 | 0.450 |
Why?
|
| Nitriles | 2 | 2017 | 6 | 0.440 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2006 | 3 | 0.440 |
Why?
|
| Ovarian Neoplasms | 5 | 2002 | 28 | 0.440 |
Why?
|
| DNA Repair | 4 | 2022 | 7 | 0.410 |
Why?
|
| Cholestanols | 2 | 2019 | 2 | 0.400 |
Why?
|
| Estrogen Receptor alpha | 4 | 2007 | 14 | 0.390 |
Why?
|
| Phosphorylation | 6 | 2019 | 68 | 0.380 |
Why?
|
| Cell Division | 11 | 2009 | 39 | 0.360 |
Why?
|
| Breast | 2 | 2021 | 8 | 0.360 |
Why?
|
| Tumor Cells, Cultured | 10 | 2013 | 67 | 0.360 |
Why?
|
| Male | 10 | 2018 | 1649 | 0.360 |
Why?
|
| Neoplasms | 2 | 2007 | 54 | 0.340 |
Why?
|
| Steroids | 2 | 2005 | 7 | 0.330 |
Why?
|
| Gene Expression | 3 | 2005 | 73 | 0.310 |
Why?
|
| MCF-7 Cells | 2 | 2019 | 17 | 0.310 |
Why?
|
| Transplantation, Heterologous | 8 | 2009 | 16 | 0.300 |
Why?
|
| Membrane Microdomains | 1 | 2006 | 4 | 0.280 |
Why?
|
| Triazoles | 1 | 2005 | 4 | 0.280 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 3 | 0.280 |
Why?
|
| Neovascularization, Pathologic | 2 | 2003 | 21 | 0.280 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 19 | 0.270 |
Why?
|
| Receptors, Steroid | 2 | 2005 | 3 | 0.270 |
Why?
|
| Growth Substances | 1 | 2005 | 6 | 0.270 |
Why?
|
| Cell Survival | 4 | 2017 | 17 | 0.260 |
Why?
|
| Glycoproteins | 2 | 2011 | 4 | 0.240 |
Why?
|
| Trastuzumab | 4 | 2019 | 20 | 0.240 |
Why?
|
| Progesterone | 2 | 2022 | 9 | 0.240 |
Why?
|
| Biomarkers, Tumor | 3 | 2018 | 32 | 0.230 |
Why?
|
| Middle Aged | 6 | 2018 | 799 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 25 | 0.230 |
Why?
|
| Androgens | 3 | 2022 | 29 | 0.220 |
Why?
|
| Anticarcinogenic Agents | 1 | 2002 | 2 | 0.220 |
Why?
|
| Aged | 5 | 2018 | 607 | 0.220 |
Why?
|
| Neoplasm Transplantation | 4 | 2011 | 14 | 0.210 |
Why?
|
| Cathepsins | 8 | 1981 | 9 | 0.210 |
Why?
|
| Tyrosine | 1 | 2001 | 6 | 0.210 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 6 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2004 | 7 | 0.200 |
Why?
|
| Survival Analysis | 2 | 2018 | 28 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2006 | 10 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 2006 | 9 | 0.190 |
Why?
|
| Receptors, Cell Surface | 4 | 2005 | 18 | 0.190 |
Why?
|
| Urinary Bladder | 6 | 1978 | 11 | 0.190 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 34 | 0.190 |
Why?
|
| Neuregulin-1 | 2 | 1999 | 2 | 0.180 |
Why?
|
| Endometrium | 5 | 1979 | 22 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 4 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2019 | 9 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 30 | 0.180 |
Why?
|
| Lysosomes | 6 | 1984 | 8 | 0.180 |
Why?
|
| Radiation Tolerance | 1 | 1999 | 4 | 0.180 |
Why?
|
| Epidermal Growth Factor | 3 | 2016 | 8 | 0.180 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 3 | 0.180 |
Why?
|
| Cytokines | 1 | 2019 | 47 | 0.180 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2019 | 8 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2018 | 119 | 0.170 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 17 | 0.170 |
Why?
|
| DNA Adducts | 2 | 1998 | 2 | 0.170 |
Why?
|
| Prognosis | 3 | 2015 | 47 | 0.170 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 22 | 0.170 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 3 | 0.160 |
Why?
|
| Benzamides | 1 | 2017 | 13 | 0.160 |
Why?
|
| CD24 Antigen | 1 | 2017 | 4 | 0.160 |
Why?
|
| Wnt3 Protein | 1 | 2017 | 6 | 0.150 |
Why?
|
| Receptors, Growth Factor | 2 | 2008 | 2 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 1 | 0.150 |
Why?
|
| Warfarin | 1 | 2016 | 1 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2016 | 2 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 81 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 92 | 0.140 |
Why?
|
| Vasopressins | 4 | 1976 | 7 | 0.140 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2015 | 1 | 0.140 |
Why?
|
| Transfection | 4 | 2005 | 46 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 5 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 1995 | 22 | 0.140 |
Why?
|
| Rats | 13 | 1985 | 432 | 0.140 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 133 | 0.130 |
Why?
|
| Antibodies, Neoplasm | 1 | 1994 | 1 | 0.130 |
Why?
|
| Peptide Hydrolases | 3 | 1979 | 5 | 0.120 |
Why?
|
| Genetic Vectors | 3 | 2005 | 16 | 0.120 |
Why?
|
| Quinazolines | 1 | 2013 | 2 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 2 | 2011 | 25 | 0.120 |
Why?
|
| Mitochondria | 2 | 2007 | 26 | 0.110 |
Why?
|
| Uterus | 2 | 1984 | 12 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2006 | 6 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 13 | 0.110 |
Why?
|
| Models, Biological | 4 | 2005 | 43 | 0.110 |
Why?
|
| AC133 Antigen | 1 | 2011 | 1 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 1 | 0.100 |
Why?
|
| Progestins | 1 | 2011 | 3 | 0.100 |
Why?
|
| Mifepristone | 1 | 2011 | 8 | 0.100 |
Why?
|
| Peptides | 1 | 2011 | 5 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2011 | 6 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 2 | 0.100 |
Why?
|
| Umbilical Cord | 1 | 2011 | 7 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2011 | 18 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 21 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2011 | 7 | 0.100 |
Why?
|
| DNA, Neoplasm | 4 | 2004 | 7 | 0.100 |
Why?
|
| Binding Sites | 5 | 2005 | 14 | 0.100 |
Why?
|
| Cathepsin D | 1 | 1990 | 2 | 0.100 |
Why?
|
| Liver | 3 | 1980 | 120 | 0.100 |
Why?
|
| Apoptosis | 3 | 2013 | 162 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1999 | 5 | 0.090 |
Why?
|
| Cyclins | 2 | 1999 | 7 | 0.090 |
Why?
|
| Epithelium | 5 | 1981 | 11 | 0.090 |
Why?
|
| Disease Progression | 1 | 2009 | 50 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 2 | 2005 | 9 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 28 | 0.090 |
Why?
|
| Cytosol | 2 | 2005 | 10 | 0.080 |
Why?
|
| Adult | 5 | 2016 | 807 | 0.080 |
Why?
|
| Subcellular Fractions | 2 | 2005 | 6 | 0.080 |
Why?
|
| Protein Transport | 1 | 2007 | 16 | 0.080 |
Why?
|
| Diethylstilbestrol | 2 | 1978 | 6 | 0.080 |
Why?
|
| Smoking | 3 | 2015 | 49 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2004 | 2 | 0.070 |
Why?
|
| Vinblastine | 2 | 2004 | 2 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 10 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2006 | 6 | 0.070 |
Why?
|
| Fluorine Radioisotopes | 1 | 2006 | 1 | 0.070 |
Why?
|
| Dideoxynucleosides | 1 | 2006 | 1 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 2 | 0.070 |
Why?
|
| RNA | 1 | 2006 | 16 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 7 | 0.070 |
Why?
|
| Androstenedione | 1 | 2005 | 6 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2005 | 18 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2005 | 12 | 0.070 |
Why?
|
| Mutation | 1 | 2006 | 28 | 0.070 |
Why?
|
| Doxorubicin | 3 | 2004 | 10 | 0.070 |
Why?
|
| COS Cells | 2 | 2005 | 2 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 12 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 1984 | 17 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2006 | 164 | 0.070 |
Why?
|
| Calcium | 2 | 1976 | 35 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2005 | 1 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 3 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 4 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 5 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 4 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 143 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2005 | 2 | 0.070 |
Why?
|
| Protein Binding | 1 | 2005 | 17 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 7 | 0.070 |
Why?
|
| Cysteine | 1 | 2005 | 2 | 0.070 |
Why?
|
| Drug Resistance | 2 | 1995 | 5 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2005 | 54 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 1984 | 3 | 0.060 |
Why?
|
| Kinetics | 2 | 2001 | 44 | 0.060 |
Why?
|
| DNA | 3 | 2005 | 19 | 0.060 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2022 | 1 | 0.060 |
Why?
|
| Hydrolases | 3 | 1981 | 3 | 0.060 |
Why?
|
| Castration | 5 | 1984 | 14 | 0.060 |
Why?
|
| Drug Synergism | 3 | 2013 | 24 | 0.060 |
Why?
|
| Cell Cycle | 2 | 1999 | 14 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 6 | 0.060 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 6 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 11 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2002 | 29 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 1999 | 27 | 0.050 |
Why?
|
| Response Elements | 1 | 2001 | 4 | 0.050 |
Why?
|
| Cell Death | 1 | 2001 | 7 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 9 | 0.050 |
Why?
|
| Acid Phosphatase | 3 | 1976 | 4 | 0.050 |
Why?
|
| Leupeptins | 2 | 1979 | 3 | 0.050 |
Why?
|
| Serum Albumin, Bovine | 1 | 2001 | 1 | 0.050 |
Why?
|
| Antibodies | 1 | 2001 | 9 | 0.050 |
Why?
|
| Nitrosamines | 2 | 1979 | 2 | 0.050 |
Why?
|
| Concanavalin A | 3 | 1978 | 3 | 0.050 |
Why?
|
| Clitoris | 1 | 1981 | 1 | 0.050 |
Why?
|
| Sebaceous Glands | 1 | 1981 | 1 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2001 | 25 | 0.050 |
Why?
|
| Rana catesbeiana | 5 | 1981 | 6 | 0.050 |
Why?
|
| In Vitro Techniques | 5 | 1981 | 37 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 1999 | 1 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 1999 | 1 | 0.040 |
Why?
|
| DNA Damage | 1 | 1999 | 16 | 0.040 |
Why?
|
| Genital Neoplasms, Female | 1 | 1979 | 6 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 32 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 1978 | 1 | 0.040 |
Why?
|
| Oligopeptides | 1 | 1978 | 3 | 0.040 |
Why?
|
| Ovary | 2 | 1975 | 12 | 0.040 |
Why?
|
| Heterografts | 1 | 2017 | 1 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 10 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 12 | 0.040 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 4 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 5 | 0.040 |
Why?
|
| Twist-Related Protein 1 | 1 | 2017 | 6 | 0.040 |
Why?
|
| beta Catenin | 1 | 2017 | 16 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 9 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 24 | 0.040 |
Why?
|
| Chest Pain | 1 | 2016 | 1 | 0.040 |
Why?
|
| Dyspnea | 1 | 2016 | 1 | 0.040 |
Why?
|
| Vitamin K | 1 | 2016 | 1 | 0.040 |
Why?
|
| Angiography | 1 | 2016 | 3 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2016 | 11 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2016 | 19 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 33 | 0.040 |
Why?
|
| Epithelial Cells | 4 | 1999 | 29 | 0.040 |
Why?
|
| Anura | 4 | 1978 | 5 | 0.040 |
Why?
|
| Proline-Rich Protein Domains | 1 | 2016 | 1 | 0.040 |
Why?
|
| Cell Growth Processes | 1 | 2016 | 4 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2016 | 8 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 3 | 0.040 |
Why?
|
| Body Water | 1 | 1976 | 5 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 1976 | 45 | 0.040 |
Why?
|
| Alkaline Phosphatase | 3 | 1981 | 6 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cell Line | 2 | 2005 | 80 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1995 | 52 | 0.030 |
Why?
|
| Glucose | 1 | 1975 | 39 | 0.030 |
Why?
|
| Hemadsorption | 1 | 1975 | 1 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 75 | 0.030 |
Why?
|
| Pseudopregnancy | 1 | 1974 | 1 | 0.030 |
Why?
|
| Smell | 1 | 1974 | 1 | 0.030 |
Why?
|
| Estrus | 1 | 1974 | 4 | 0.030 |
Why?
|
| Glucuronidase | 3 | 1979 | 3 | 0.030 |
Why?
|
| Testosterone | 1 | 1974 | 76 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 12 | 0.030 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1984 | 2 | 0.030 |
Why?
|
| Cell Fractionation | 2 | 1984 | 3 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 116 | 0.030 |
Why?
|
| Pregnancy | 3 | 1979 | 305 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2004 | 13 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2004 | 13 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2011 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1997 | 118 | 0.030 |
Why?
|
| Hydrocortisone | 3 | 1975 | 27 | 0.030 |
Why?
|
| Nucleotidases | 2 | 1981 | 2 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1984 | 11 | 0.020 |
Why?
|
| Membrane Potentials | 2 | 1984 | 11 | 0.020 |
Why?
|
| Cholesterol | 2 | 1981 | 21 | 0.020 |
Why?
|
| Acetylglucosaminidase | 2 | 1979 | 2 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 1979 | 13 | 0.020 |
Why?
|
| Carbon Dioxide | 2 | 1981 | 12 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 1979 | 77 | 0.020 |
Why?
|
| Beverages | 1 | 2006 | 3 | 0.020 |
Why?
|
| Rabbits | 2 | 1978 | 25 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 3 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2006 | 15 | 0.020 |
Why?
|
| Glioma | 1 | 1985 | 2 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 95 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2006 | 121 | 0.020 |
Why?
|
| Temperature | 2 | 1975 | 3 | 0.020 |
Why?
|
| Electric Conductivity | 2 | 1975 | 3 | 0.020 |
Why?
|
| Permeability | 2 | 1975 | 3 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2005 | 3 | 0.020 |
Why?
|
| Stimulation, Chemical | 2 | 1975 | 14 | 0.020 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 1 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 9 | 0.020 |
Why?
|
| Bufo marinus | 2 | 1975 | 2 | 0.020 |
Why?
|
| Sodium | 2 | 1975 | 28 | 0.020 |
Why?
|
| Receptors, Estradiol | 1 | 1984 | 1 | 0.020 |
Why?
|
| Floxuridine | 1 | 2004 | 1 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2004 | 1 | 0.020 |
Why?
|
| Epirubicin | 1 | 2004 | 1 | 0.020 |
Why?
|
| Carboplatin | 1 | 2004 | 1 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2004 | 2 | 0.020 |
Why?
|
| Taxoids | 1 | 2004 | 6 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1984 | 1 | 0.020 |
Why?
|
| Coated Pits, Cell-Membrane | 1 | 1984 | 1 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1984 | 1 | 0.020 |
Why?
|
| Pinocytosis | 1 | 1984 | 1 | 0.020 |
Why?
|
| Mitogens | 1 | 1984 | 2 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1984 | 2 | 0.020 |
Why?
|
| Endocytosis | 1 | 1984 | 2 | 0.020 |
Why?
|
| Cell Communication | 1 | 1984 | 5 | 0.020 |
Why?
|
| Thyrotropin | 1 | 1984 | 6 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2004 | 71 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1984 | 18 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1984 | 15 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1984 | 79 | 0.010 |
Why?
|
| Ions | 1 | 2003 | 2 | 0.010 |
Why?
|
| Nerve Tissue | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2003 | 15 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1981 | 3 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1981 | 38 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1981 | 5 | 0.010 |
Why?
|
| Cathepsin B | 1 | 1981 | 2 | 0.010 |
Why?
|
| Lectins | 1 | 1980 | 4 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 1999 | 1 | 0.010 |
Why?
|
| Receptor, ErbB-4 | 1 | 1999 | 1 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1979 | 7 | 0.010 |
Why?
|
| Proteins | 1 | 1979 | 17 | 0.010 |
Why?
|
| Receptors, Concanavalin A | 1 | 1979 | 1 | 0.010 |
Why?
|
| Liposomes | 1 | 1979 | 2 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 1 | 0.010 |
Why?
|
| Etoposide | 1 | 1999 | 1 | 0.010 |
Why?
|
| Thiotepa | 1 | 1999 | 1 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1999 | 1 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1999 | 1 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1999 | 4 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1999 | 4 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 4 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1999 | 15 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1979 | 1 | 0.010 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1979 | 2 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1979 | 13 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1979 | 19 | 0.010 |
Why?
|
| Sialyltransferases | 1 | 1978 | 1 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1978 | 2 | 0.010 |
Why?
|
| Fetus | 1 | 1978 | 96 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 1997 | 1 | 0.010 |
Why?
|
| Retroviridae | 1 | 1997 | 2 | 0.010 |
Why?
|
| Adolescent | 1 | 1978 | 305 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1997 | 7 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1977 | 8 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1976 | 1 | 0.010 |
Why?
|
| Surface Properties | 1 | 1975 | 2 | 0.010 |
Why?
|
| Extracellular Space | 1 | 1975 | 3 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1975 | 1 | 0.010 |
Why?
|
| Water | 1 | 1975 | 7 | 0.010 |
Why?
|
| Aldosterone | 1 | 1975 | 6 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1975 | 13 | 0.010 |
Why?
|
| Calcium Radioisotopes | 1 | 1975 | 1 | 0.010 |
Why?
|
| Alcohols | 1 | 1975 | 1 | 0.010 |
Why?
|
| Methylmannosides | 1 | 1975 | 1 | 0.010 |
Why?
|
| Ouabain | 1 | 1975 | 1 | 0.010 |
Why?
|
| Hemagglutination | 1 | 1975 | 2 | 0.010 |
Why?
|
| Potassium | 1 | 1975 | 6 | 0.010 |
Why?
|
| Biological Transport | 1 | 1975 | 13 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 1975 | 8 | 0.010 |
Why?
|
| Amino Acids | 1 | 1975 | 16 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1975 | 13 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1975 | 9 | 0.010 |
Why?
|
| Time Factors | 1 | 1975 | 120 | 0.010 |
Why?
|
| Reaction Time | 1 | 1974 | 8 | 0.010 |
Why?
|
| Ovulation | 1 | 1974 | 3 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 1974 | 10 | 0.010 |
Why?
|
| Conditioning, Operant | 1 | 1974 | 13 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 1974 | 24 | 0.010 |
Why?
|